New hope for DMD: Long-Term drug trial aims to preserve muscle function

NCT ID NCT07573631

First seen May 09, 2026 · Last updated May 24, 2026 · Updated 3 times

Summary

This study looks at the long-term safety and effects of a weekly IV drug called BMN 351 in people with Duchenne muscular dystrophy (DMD) whose genetic makeup allows for exon 51 skipping. Participants must have completed a prior study of the same drug. The goal is to see if the drug is safe over time and if it helps maintain physical abilities like walking and climbing stairs.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY (DMD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Fondazione Serena ETS - Centro Clinico NeMO Milano

    Milan, Italy

  • Great Ormond Street Hospital NHS Foundation Trust

    London, WC1N 3JH, United Kingdom

  • Hospital Sant Joan de Deu

    Barcelona, 08950, Spain

  • Hospital Viamed Santa Angela De la Cruz

    Seville, 41013, Spain

  • Leids Universitair Medisch Centrum

    Leiden, 2333 ZA, Netherlands

  • UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore

    Rome, Italy

  • Yeditepe University Kosuyolu Hospital

    Istanbul, Turkey, Turkey (Türkiye)

Conditions

Explore the condition pages connected to this study.